Navigation Links
Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
Date:9/23/2011

SAN DIEGO, Sept. 23, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR™ (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea (CDAD).

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

DIFICLIR, which is known as DIFICID™ in the United States (US), was approved by the US FDA in May 2011 for the treatment of CDAD in adults 18 years of age and older. Astellas is Optimer's exclusive licensee to develop and commercialize DIFICLIR in Europe and certain other countries in the Middle East, Africa and the Commonwealth of Independent States.

The CHMP positive opinion is based on Phase 3 clinical studies that were conducted to compare the safety and efficacy of 400mg/day fidaxomicin with 500mg/day oral vancomycin for 10 days in subjects with CDI. The first Phase 3 study was carried out in 629 subjects in North America (US and Canada). The second Phase 3 study was carried out in 535 subjects in North America and Europe. The results of the studies showed that the proportion of subjects in which clinical cure was achieved at the end of 10 days of treatment were similar for both treatments; thus fidaxomicin met its primary endpoint of non-inferiority to vancomycin. Furthermore in both trials, fidaxomicin had a significantly lower rate of recurrence of CDI compared to vancomycin at 30 days after completion of treatment.

"A positive CHMP opinion is an important milestone for Optimer and is a key step to making fidaxomicin more widely available to patients around the globe for this serious dis
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
2. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
3. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
6. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
7. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
8. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
10. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
11. Optimer Pharmaceuticals Expands Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/d8nj6b/europe ) ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... market for Fluoroscopy is expected to grow at a ... is used to view the gastrointestinal tract, to direct ... ducts or the urinary system, to open narrowed or ...
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/w3n5p6/drug_delivery_in ) has ... "Drug Delivery in Central Nervous System Diseases ... offering. The delivery of drugs to ... the treatment of neurological disorders. Drugs may be ... (e.g., by intravenous injection) for targeted action in ...
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/z9s8mp/laboratory ) has ... - Global Strategic Business Report" report to ... are provided for the period 2014 through 2020. ... these markets. Market data and analytics are derived ... primarily based on public domain information including company ...
Breaking Medicine Technology:European Fluoroscopy Market Report 2014-2019 - Growth, Trends And Forecasts 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3Laboratory Centrifuges - Global Strategic Business Report 2014-2020: Developed Markets Slowdown, While Emerging Markets Surge 2
... TAINAN, Taiwan, Nov. 19 /PRNewswire-Asia/ ... ingredients (APIs), announced that its,Tainan facility has received ... The Certification confirms ScinoPharm,s,competency and proficiency in the ... applies to specific laboratories and,production areas used for ...
... , CAMBRIDGE, Mass., Nov. 19 Ligon ... to find drugs against high-value targets, today announced that ... incTANK Ventures. The company will use the capital to ... 100 high-value disease protein targets. With this investment, incTANK ...
Cached Medicine Technology:ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3
(Date:6/2/2015)... (PRWEB) June 02, 2015 The 3TVPhoenix contest, ... to watch the station’s 6:00 a.m. Good Morning Arizona program ... on the station’s Facebook page. , Lisa Allen ... participants. She plans to apply the monthly $1,000 prize ... Allen, a stay-at-home mom, expressed her surprise and gratitude at ...
(Date:6/2/2015)... India (PRWEB) June 02, 2015 Bitscape ... in the 2015 Microsoft Worldwide Small and Midsized Cloud ... field of top Microsoft partners for demonstrating excellence in ... technology. , “This comes as no surprise to ... recognized third year consecutively at worldwide level by Microsoft. ...
(Date:6/2/2015)... HERSHEY, Pa. (PRWEB) June 02, 2015 ... honored as one of the 30 members of the ... State College of Medicine. He was presented with a ... field. , “We are extremely proud of Vincent’s ... Gurt ’85. “He is a great example of how ...
(Date:6/2/2015)... RI (PRWEB) June 02, 2015 ... equipment distributor, has announced the acquisition of ... equipment distributor, effective May 29th, 2015. , With CME’s ... 2015, this latest acquisition joins three premier organizations which ... to hospitals and healthcare facilities. By combining forces, they ...
(Date:6/2/2015)... Mo. (PRWEB) June 02, 2015 With a ... Senior Living & Health Care has hired Leslie Young ... expansion of human resource initiatives to better understand and respond ... families in Tutera’s 47 communities in 13 states across the ... highest levels of personalized support to our residents, we are ...
Breaking Medicine News(10 mins):Health News:Scottsdale Resident Named $12,000 Prize Winner- Arizona Central and KTVK 3TV Phoenix Partner in Mortgage Giveaway Contest 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 3Health News:Claflin Medical Equipment (CME) Announces Acquisition of RSI Equipment, Inc. 2Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 2Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 3Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 4
... tremor, a very common movement disorder, increases in incidence ... While voice tremors are not uncommon, the condition can ... it.// ,Previous treatments for voice tremor, such ... and are primarily recommended for treating hand tremors. Researchers ...
... recent study shows a completely artificial heart could prevent ... candidates for a heart transplant . The artificial heart ... and after transplantation. // ,The artificial heart ... transplantation in many patients who did not improve with ...
... Breast cancer may be detected earlier using a computer-assisted ... study. CAD is a computer-based analysis designed to find ... that appear only as tiny white specks on mammography ... ,Researchers reviewed the cases of 519 patients ...
... Researchers are now saying that the gene known as “mighty ... Studies on this gene arose when a German neurologist , ... well-developed muscles. Further tests revealed the child had a mutation ... producing the myostatin protein, which is known to regulate muscle ...
... found to boost the immune system and help fight off ... on children already in the hospital with severe pneumonia// and ... children with severe pneumonia recover quicker . ,The study ... About half received 20 milligrams of zinc per day while ...
... loss of liver function that can cause death within ... supportive care intended to keep patients alive long enough ... donor organ becomes available for transplantation. About 80 percent ... transplant. ,A bioartificial liver along with pig stem ...
Cached Medicine News:
... The AQT-10 is the ultimate in ... designed to detect the subtle red/green or ... disorders as retinal toxicity (that from Plaquenil, ... retinopathy, and macular degeneration. Additionally it is ...
... Amplifier (UBA-4204) from LKC Technologies, ... amplification and complete electrical isolation ... problems of DC drifting, 50/60Hz ... make the amplifier ideal for ...
... PACHETT 3 uses the exact enhanced corneal ... DGH pachymeters used exclusively by the OHTS ... into the software. The new backlit LCD ... average, standard deviation and IOP correction calculation ...
Orbital Retractor, schepens Retractors, overall length:154mm....
Medicine Products: